4/12/2013

The PET Response Criteria in Solid Tumors and criteria from the European Organization for Research and Treatment of Cancer are similarly useful for measuring the response of patients with colorectal cancer to cycles of irinotecan and cetuximab using PET/CT, according to a study published in The Journal of Nuclear Medicine. However, the researchers found that PERCIST was better suited for widespread use because the criteria were less sensitive to differences between observers, allowing for greater consistency.

Related Summaries